Hims & Hers Health (NYSE:HIMS) Raised to Hold at Zacks Research

Hims & Hers Health (NYSE:HIMS) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

HIMS has been the subject of several other reports. JPMorgan Chase & Co. reduced their target price on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Jefferies Financial Group set a $24.50 price target on Hims & Hers Health in a research note on Tuesday, May 12th. Needham & Company LLC raised their price target on Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, May 12th. Truist Financial lifted their price objective on shares of Hims & Hers Health from $18.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, May 22nd. Finally, Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $25.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, May 5th. Four research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $30.70.

Hims & Hers Health Stock Up 2.2%

Shares of HIMS stock opened at $35.14 on Monday. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $70.43. The stock has a market cap of $8.13 billion, a price-to-earnings ratio of -390.43, a PEG ratio of 96.75 and a beta of 2.35. The firm’s 50-day moving average is $29.69 and its 200-day moving average is $26.34. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims & Hers Health’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period last year, the firm earned $0.20 EPS. Sell-side analysts predict that Hims & Hers Health will post 0.03 EPS for the current year.

Insider Activity

In related news, insider Soleil Boughton sold 9,463 shares of the company’s stock in a transaction dated Monday, April 20th. The shares were sold at an average price of $30.00, for a total value of $283,890.00. Following the transaction, the insider directly owned 299,368 shares in the company, valued at approximately $8,981,040. This represents a 3.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Oluyemi Okupe sold 36,922 shares of the firm’s stock in a transaction dated Thursday, April 16th. The stock was sold at an average price of $25.90, for a total transaction of $956,279.80. Following the transaction, the chief financial officer directly owned 281,867 shares in the company, valued at approximately $7,300,355.30. This represents a 11.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 167,161 shares of company stock worth $5,041,152. Corporate insiders own 11.76% of the company’s stock.

Institutional Trading of Hims & Hers Health

Several hedge funds and other institutional investors have recently bought and sold shares of HIMS. Vanguard Group Inc. boosted its holdings in Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares during the period. State Street Corp increased its holdings in shares of Hims & Hers Health by 1.8% during the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock worth $237,210,000 after purchasing an additional 132,311 shares during the period. Geode Capital Management LLC raised its position in shares of Hims & Hers Health by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after buying an additional 608,950 shares in the last quarter. Bank of America Corp DE raised its position in shares of Hims & Hers Health by 194.4% in the first quarter. Bank of America Corp DE now owns 4,357,672 shares of the company’s stock valued at $90,465,000 after buying an additional 2,877,550 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Hims & Hers Health by 62.7% in the third quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after buying an additional 1,600,004 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.